Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 17

1.

Randomized phase II study of 5-fluorouracil hepatic arterial infusion with or without antineoplastons as an adjuvant therapy after hepatectomy for liver metastases from colorectal cancer.

Ogata Y, Matono K, Tsuda H, Ushijima M, Uchida S, Akagi Y, Shirouzu K.

PLoS One. 2015 Mar 19;10(3):e0120064. doi: 10.1371/journal.pone.0120064. eCollection 2015.

2.

Demethylation effect of the antineoplaston AS2-1 on genes in colon cancer cells.

Ushijima M, Ogata Y, Tsuda H, Akagi Y, Matono K, Shirouzu K.

Oncol Rep. 2014 Jan;31(1):19-26. doi: 10.3892/or.2013.2839. Epub 2013 Nov 8.

3.

Antineoplaston induces G(1) arrest by PKCalpha and MAPK pathway in SKBR-3 breast cancer cells.

Fujii T, Nakamura AM, Yokoyama G, Yamaguchi M, Tayama K, Miwa K, Toh U, Kawamura D, Shirouzu K, Yamana H, Kuwano M, Tsuda H.

Oncol Rep. 2005 Aug;14(2):489-94.

PMID:
16012735
4.

Effects of antineoplaston AS2-1 against post-operative lung metastasis in orthotopically implanted colon cancer in nude rat.

Matono K, Ogata Y, Tsuda H, Araki Y, Shirouzu K.

Oncol Rep. 2005 Mar;13(3):389-95.

PMID:
15706406
5.

Long-term survival following treatment with antineoplastons for colon cancer with unresectable multiple liver metastases: report of a case.

Ogata Y, Tsuda H, Matono K, Kumabe T, Saitsu H, Hara H, Akagi Y, Araki Y, Sata M, Shirouzu K.

Surg Today. 2003;33(6):448-53.

PMID:
12768372
6.

The preventive effect of antineoplaston AS2-1 on HCC recurrence.

Tsuda H, Sata M, Kumabe T, Uchida M, Hara H.

Oncol Rep. 2003 Mar-Apr;10(2):391-7.

PMID:
12579278
7.

A novel strategy for remission induction and maintenance in cancer therapy.

Tsuda H, Sata M, Ijuuin H, Kumabe T, Uchida M, Ogou Y, Akagi Y, Shirouzu K, Hara H, Nakashima Y.

Oncol Rep. 2002 Jan-Feb;9(1):65-8.

PMID:
11748457
8.

Antineoplaston treatment for advanced hepatocellular carcinoma.

Kumabe T, Tsuda H, Uchida M, Ogoh Y, Hayabuchi N, Sata M, Nakashima O, Hara H.

Oncol Rep. 1998 Nov-Dec;5(6):1363-7.

PMID:
9769368
9.

Quick response of advanced cancer to chemoradiation therapy with antineoplastons.

Tsuda H, Sata M, Kumabe T, Hara H, Eriguchi N, Sugita Y, Nagamatsu H.

Oncol Rep. 1998 May-Jun;5(3):597-600.

PMID:
9538158
10.

Antineoplaston AS2-1 for maintenance therapy in liver cancer.

Tsuda H, Sata M, Saitsu H, Yamana K, Hara H, Yamada S, Kumabe T.

Oncol Rep. 1997 Nov-Dec;4(6):1213-6.

PMID:
21590224
11.

Inhibitory effect of antineoplaston A10 and AS2-1 on human hepatocellular carcinoma.

Tsuda H, Iemura A, Sata M, Uchida M, Yamana K, Hara H.

Kurume Med J. 1996;43(2):137-47.

12.

Toxicological study on antineoplastons A-10 and AS2-1 in cancer patients.

Tsuda H, Hara H, Eriguchi N, Nishida H, Yoshida H, Kumabe T, Sugita Y.

Kurume Med J. 1995;42(4):241-9.

13.

The effect of Antineoplaston, a new antitumor agent on malignant brain tumors.

Sugita Y, Tsuda H, Maruiwa H, Hirohata M, Shigemori M, Hara H.

Kurume Med J. 1995;42(3):133-40.

14.

The inhibitory effect of the combination of antineoplaston A-10 injection with a small dose of cis-diamminedichloroplatinum on cell and tumor growth of human hepatocellular carcinoma.

Tsuda H, Sugihara S, Nishida H, Hara H, Eriguchi N, Ishii K, Sasaki K, Yoshimura S, Tanaka N.

Jpn J Cancer Res. 1992 May;83(5):527-31.

15.

The anticancer effect of antineoplaston A-10 on human breast cancer serially transplanted to athymic mice.

Hashimoto K, Koga T, Shintomi Y, Tanaka M, Kakegawa T, Tsuda H, Hara H.

Nihon Gan Chiryo Gakkai Shi. 1990 Jan 20;25(1):1-5.

PMID:
2157780
17.

Chemopreventive effect of antineoplaston A-10 on urethane-induced pulmonary neoplasm in mice.

Eriguchi N, Hara H, Yoshida H, Nishida H, Nakayama T, Ohishi K, Tsuda H, Inoue S, Ikeda I.

Nihon Gan Chiryo Gakkai Shi. 1988 Jul 20;23(7):1560-5. No abstract available.

PMID:
3183462

Supplemental Content

Loading ...
Support Center